Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report) shares passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $0.01 and traded as low as $0.0009. Nascent Biotech shares last traded at $0.0009, with a volume of 13,000 shares.
Nascent Biotech Price Performance
The company’s 50-day moving average price is $0.01.
Nascent Biotech Company Profile
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation.
Featured Stories
- Five stocks we like better than Nascent Biotech
- Do not delete, read immediately
- [How To] Claim Your Pre-IPO Stake In SpaceX!
- Can Any Expenses Be Deducted From Capital Gains Tax?
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
- “Ominous day” coming to stocks…
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
